Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Tempest Therapeutics Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial October 10, 2024 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest Extends Limited Duration Stockholder Rights Plan October 10, 2024 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 20, 2024 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs September 18, 2024 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 05, 2024 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) August 23, 2024 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance August 21, 2024 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma August 15, 2024 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update August 08, 2024 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm June 20, 2024 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma June 18, 2024 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) June 07, 2024 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest to Participate in Upcoming Investor Conferences May 21, 2024 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest Reports First Quarter 2024 Financial Results and Provides Business Update May 09, 2024 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) April 26, 2024 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting April 09, 2024 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications April 04, 2024 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest Reports Year End 2023 Financial Results and Provides Business Update March 19, 2024 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types March 12, 2024 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting March 05, 2024 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest to Present at the 44th Annual TD Cowen Healthcare Conference February 26, 2024 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) February 02, 2024 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) January 05, 2024 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) December 01, 2023 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference November 20, 2023 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update November 08, 2023 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest Adopts Limited Duration Stockholder Rights Plan October 11, 2023 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study October 11, 2023 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma October 10, 2023 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development September 19, 2023 From Tempest Therapeutics Via GlobeNewswire Tickers TPST Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
